Document Detail


Why do I treat HBeAg-positive chronic hepatitis B patients with a Nucleoside analogue.
MedLine Citation:
PMID:  23286857     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Chronic hepatitis B (CHB) is a worldwide public health problem which represents an enormous economic and social burden. Convincing evidence has shown that persistent active viral replication is an independent predictor of disease progression. Therefore, sustained suppression of HBV replication is the cornerstone for preventing the progression of disease and prolonging survival in patients with CHB. Pivotal clinical trials and real-world studies show that nucleos(t)ide analogues (NAs) are potent suppressors of HBV DNA replication with very good safety profiles. Although 1-year treatment with NAs only results in a modest rate of HBeAg seroconversion, extended treatment could increase this rate. Profound suppression of HBV DNA can result in histological improvement and a clinical benefit with a decrease in disease progression in patients with compensated or decompensated cirrhosis. Treatment must be begun with a highly potent and low resistant regimen to obtain long-term suppression of viral replication. An alternative solution may be a roadmap approach in which an inexpensive antiviral drug is started and another drug is added-on or switched-to if there is a suboptimal on-treatment decrease in HBV DNA. Clinical evidence has shown that once HBV DNA is suppressed and long-term HBeAg seroconversion is achieved, NAs can be stopped. In summary, high antiviral efficacy, excellent tolerance, extensive applicability, clearly proven histological improvement and long-term clinical benefit all make NAs the preferred choice for the management of CHB in most patients.
Authors:
Hong Ma; Jidong Jia
Related Documents :
16172697 - Synthetic studies toward the kempane diterpenes. construction of a key tricyclic interm...
2506807 - Production of extracellular nucleic acids by genetically altered bacteria in aquatic-en...
8797387 - Peptide nucleic acid characterization by maldi-tof mass spectrometry.
11433037 - Rapid characterization of dna oligomers and genotyping of single nucleotide polymorphis...
7595217 - Nitric oxide potentiates hydrogen peroxide-induced killing of escherichia coli.
17143267 - Pgc7/stella protects against dna demethylation in early embryogenesis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  133-6     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Affiliation:
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of HBsAg quantification for monitoring natural history and treatment outcome.
Next Document:  Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.